المؤلفون: Huang Z; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Chen T; Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China., Li W; Department of Biliopancreatic Surgery, Sun Yat-sen Memorial Hospital, Guangzhou, China., He W; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Liu S; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Wu Z; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Li B; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Yuan Y; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China., Qiu J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address: qiujl@sysucc.org.cn.

المصدر: International immunopharmacology [Int Immunopharmacol] 2024 Sep 30; Vol. 139, pp. 112711. Date of Electronic Publication: 2024 Jul 18.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/therapy , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/therapy , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use , Chemoembolization, Therapeutic*/methods , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Infusions, Intra-Arterial*, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Tumor Burden ; Hepatic Artery ; Treatment Outcome ; Combined Modality Therapy ; Cohort Studies

المؤلفون: Garcia P; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.; R&D Department, Inovotion, La Tronche, France., Wang Y; R&D Department, Inovotion, La Tronche, France., Viallet J; R&D Department, Inovotion, La Tronche, France., Mehdi NEH; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France., Montaut E; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.; Pôle Recherche, CHU Grenoble Alpes, La Tronche, France., Decaens T; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.; Service d'Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble Alpes, La Tronche, France., Emadali A; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.; Pôle Recherche, CHU Grenoble Alpes, La Tronche, France., Macek Jílková Z; Univ. Grenoble Alpes, Inserm U 1209, CNRS UMR 5309, Institute for Advanced Biosciences, Grenoble, France.; Service d'Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble Alpes, La Tronche, France.

المصدر: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2024 Sep 15; Vol. 38 (17), pp. e70029.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Federation of American Societies for Experimental Biology Country of Publication: United States NLM ID: 8804484 Publication Model: Print Cited Medium: Internet ISSN: 1530-6860 (Electronic) Linking ISSN: 08926638 NLM ISO Abbreviation: FASEB J Subsets: MEDLINE

مواضيع طبية MeSH: Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/immunology , Bevacizumab*/therapeutic use , Bevacizumab*/pharmacology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/pharmacology , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/immunology, Animals ; Humans ; Chick Embryo ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Tumor Microenvironment/drug effects ; Immunotherapy/methods ; Chorioallantoic Membrane/drug effects ; Disease Models, Animal

المؤلفون: Bando H; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kotani D; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Satake H; Department of Medical Oncology, Kochi Medical School/Kansai Medical University, Nankoku, Japan. Electronic address: takeh1977@gmail.com., Hamaguchi T; Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Saitama, Japan., Shiozawa M; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan., Kotaka M; Gastrointestinal Cancer Center, Sano Hospital, Hyogo, Japan., Masuishi T; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan., Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan., Kagawa Y; Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan., Komatsu Y; Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan., Oki E; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Yamamoto Y; Department of Gastroenterology, University of Tsukuba Hospital, Ibaraki, Japan., Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan., Misumi T; Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan., Taniguchi H; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan., Yamazaki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan., Yoshino T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kato T; Department of Surgery, NHO Osaka National Hospital, Osaka, Japan., Tsuji A; Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan.

المصدر: Med (New York, N.Y.) [Med] 2024 Sep 13; Vol. 5 (9), pp. 1164-1177.e3. Date of Electronic Publication: 2024 Jun 19.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101769215 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6340 (Electronic) Linking ISSN: 26666340 NLM ISO Abbreviation: Med Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/mortality , Colorectal Neoplasms*/pathology , Leucovorin*/therapeutic use , Leucovorin*/administration & dosage , Leucovorin*/adverse effects , Fluorouracil*/administration & dosage , Fluorouracil*/therapeutic use , Fluorouracil*/adverse effects , Organoplatinum Compounds*/therapeutic use , Organoplatinum Compounds*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Capecitabine/adverse effects ; Progression-Free Survival ; Oxaliplatin/administration & dosage ; Oxaliplatin/therapeutic use ; Oxaliplatin/adverse effects ; Camptothecin/analogs & derivatives ; Camptothecin/administration & dosage ; Camptothecin/therapeutic use ; Camptothecin/adverse effects ; Irinotecan/therapeutic use ; Irinotecan/administration & dosage ; Irinotecan/adverse effects

SCR Protocol: FOLFOXIRI protocol

المؤلفون: Sanoff HK; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, United States., Deal AM; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States., Patel J; Levine Cancer Center, Charlotte, NC 28204, United States., Sorah JD; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, United States., Gaddy J; Division of Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT 06520, United States., O'Neil B; Community Health System, Indianapolis, IN 46250, United States., Turk A; Division of Hematology/Oncology, Indiana University, Indianapolis, IN 46202, United States., Irvin W; Bon Secours Cancer Institute, Richmond, VA 23114, United States., Boles J; UNC Rex Hematology/Oncology, Raleigh, NC 27607, United States., Lee MS; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., McRee A; The Janssen Research and Development, Spring House, PA 19002, United States., Wardell AC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States., Weck KE; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27514, United States., Basch E; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, United States., Wood WA; Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27514, United States.; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, United States., Innocenti F; Division of Pharmacotherapy and Experimental Therapeutics, Eschelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27514, United States.

المصدر: The oncologist [Oncologist] 2024 Sep 06; Vol. 29 (9), pp. 786-793.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colorectal Neoplasms*/pathology , Bevacizumab*/administration & dosage , Bevacizumab*/pharmacology , Bevacizumab*/therapeutic use , Bevacizumab*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Glucuronosyltransferase*/genetics , Leucovorin*/administration & dosage , Leucovorin*/therapeutic use , Leucovorin*/adverse effects , Camptothecin*/analogs & derivatives , Camptothecin*/therapeutic use , Camptothecin*/administration & dosage , Camptothecin*/adverse effects , Camptothecin*/pharmacology , Fluorouracil*/administration & dosage , Fluorouracil*/adverse effects , Fluorouracil*/therapeutic use , Genotype*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Irinotecan/administration & dosage ; Irinotecan/therapeutic use ; Irinotecan/adverse effects ; Irinotecan/pharmacology

SCR Protocol: IFL protocol

المؤلفون: Lee Y; Department of Neurosurgery, Ajou University School of Medicine, Suwon, Korea., Lee E; Department of Neurology, McGovern Medical School at UTHealth, Houston, TX, USA., Roh TH; Department of Neurosurgery, Ajou University School of Medicine, Suwon, Korea. throh@ajou.ac.kr., Kim SH; Department of Neurosurgery, Ajou University School of Medicine, Suwon, Korea.

المصدر: Journal of Korean medical science [J Korean Med Sci] 2024 Sep 02; Vol. 39 (34), pp. e244. Date of Electronic Publication: 2024 Sep 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Korean Academy of Medical Science Country of Publication: Korea (South) NLM ID: 8703518 Publication Model: Electronic Cited Medium: Internet ISSN: 1598-6357 (Electronic) Linking ISSN: 10118934 NLM ISO Abbreviation: J Korean Med Sci Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/therapeutic use , Bevacizumab*/administration & dosage , Irinotecan*/therapeutic use , Glioblastoma*/drug therapy , Glioblastoma*/mortality , Glioblastoma*/therapy , Glioblastoma*/pathology , Neoplasm Recurrence, Local* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Adult ; Aged ; Brain Neoplasms/drug therapy ; Brain Neoplasms/therapy ; Brain Neoplasms/mortality ; Temozolomide/therapeutic use ; Kaplan-Meier Estimate ; Retrospective Studies ; Chemoradiotherapy ; Databases, Factual

المؤلفون: Kimura M; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan., Nishikawa K; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan., Imamura J; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan., Kimura K; Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Bunkyo-ku, Tokyo, Japan.

المصدر: Cancer medicine [Cancer Med] 2024 Sep; Vol. 13 (18), pp. e70217.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/therapy , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/mortality , Liver Neoplasms*/therapy , Quinolines*/therapeutic use , Quinolines*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Phenylurea Compounds*/therapeutic use , Phenylurea Compounds*/administration & dosage , Bevacizumab*/therapeutic use , Bevacizumab*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Retrospective Studies ; Aged ; Middle Aged ; Neoplasm Staging ; Aged, 80 and over ; Adult ; Treatment Outcome

المؤلفون: Wijaya ST; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Ngoi NY; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Loh JW; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Tan TZ; Cancer Science Institute of Singapore, National University of Singapore, Singapore.; Genomics and Data Analytics Core (GeDaC), Cancer Science Institute of Singapore, National University of Singapore, Singapore., Lim D; Department of Pathology, National University Health System, Singapore., Khan IS; Department of Pathology, National University Health System, Singapore., Thian YL; Department of Diagnostic Imaging, National University Health System, Singapore., Lai A; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Ang BW; Department of Diagnostic Imaging, National University Health System, Singapore., Tong P; Division of Gynaecologic Oncology, Department of Obstetrics & Gynaecology, National University Hospital, Singapore., Ng J; Division of Gynaecologic Oncology, Department of Obstetrics & Gynaecology, National University Hospital, Singapore., Low JJ; Division of Gynaecologic Oncology, Department of Obstetrics & Gynaecology, National University Hospital, Singapore., Ilancheran A; Division of Gynaecologic Oncology, Department of Obstetrics & Gynaecology, National University Hospital, Singapore., Lim SE; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Lim YW; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore., Tan DS; Cancer Science Institute of Singapore, National University of Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; NUS Centre for Cancer Research (N2CR), National University of Singapore, Singapore. David_sp_tan@nuhs.edu.sg.

المصدر: Journal of gynecologic oncology [J Gynecol Oncol] 2024 Sep; Vol. 35 (5), pp. e69. Date of Electronic Publication: 2024 Mar 29.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Asian Society of Gynecologic Oncology Country of Publication: Korea (South) NLM ID: 101483150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-0399 (Electronic) Linking ISSN: 20050380 NLM ISO Abbreviation: J Gynecol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cytoreduction Surgical Procedures* , Ovarian Neoplasms*/genetics , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/surgery , Ovarian Neoplasms*/mortality , Ovarian Neoplasms*/pathology , Ovarian Neoplasms*/therapy , Bevacizumab*/administration & dosage , Bevacizumab*/therapeutic use, Humans ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Adenocarcinoma, Clear Cell/genetics ; Adenocarcinoma, Clear Cell/pathology ; Adenocarcinoma, Clear Cell/drug therapy ; Adenocarcinoma, Clear Cell/surgery ; Adenocarcinoma, Clear Cell/therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; High-Throughput Nucleotide Sequencing ; Transcription Factors/genetics ; DNA-Binding Proteins/genetics ; Immune Checkpoint Inhibitors/therapeutic use ; Molecular Targeted Therapy ; Aged, 80 and over ; Nuclear Proteins/genetics ; Mutation ; Progression-Free Survival ; Class I Phosphatidylinositol 3-Kinases/genetics ; Treatment Outcome

المؤلفون: Zuluaga-Botero C; Grupo de investigación Visión y Salud Ocular-VISOC, Universidad del Valle, Cali, Colombia; Departamento de Oftalmología, Clínica Imbanaco Grupo QuirónSalud, Cali, Colombia; Instituto para Niños Ciegos y Sordos del Valle del Cauca, Cali, Colombia., González N; Especialización en Oftalmología, Pontificia Universidad Javeriana Cali, Cali, Colombia., Escobar G; Departamento de Oftalmología, Clínica Imbanaco Grupo QuirónSalud, Cali, Colombia., Cantor E; Departamento de Epidemiología Clínica y Bioestadística, Pontificia Universidad Javeriana, Bogotá, Colombia., Martínez-Blanco A; Grupo de investigación Visión y Salud Ocular-VISOC, Universidad del Valle, Cali, Colombia; Departamento de Oftalmología, Clínica Imbanaco Grupo QuirónSalud, Cali, Colombia. Electronic address: Alexander.m.martinez@correounivalle.edu.co.

المصدر: Archivos de la Sociedad Espanola de Oftalmologia [Arch Soc Esp Oftalmol (Engl Ed)] 2024 Sep; Vol. 99 (9), pp. 400-403. Date of Electronic Publication: 2024 May 18.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: Elsevier España Country of Publication: Spain NLM ID: 101715860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2173-5794 (Electronic) Linking ISSN: 21735794 NLM ISO Abbreviation: Arch Soc Esp Oftalmol (Engl Ed) Subsets: MEDLINE

مواضيع طبية MeSH: Retinopathy of Prematurity*/drug therapy , Bevacizumab*/therapeutic use , Bevacizumab*/administration & dosage , Intravitreal Injections* , Angiogenesis Inhibitors*/therapeutic use , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/adverse effects, Humans ; Infant, Newborn ; Male ; Female ; Colombia ; Retrospective Studies ; Treatment Outcome ; Vascular Endothelial Growth Factor A/antagonists & inhibitors

المؤلفون: Al-Jilaihawi S; Department of Paediatric Oncology, Bristol Royal Hospital for Children, Bristol, UK., Spreafico F; Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Mavinkurve-Groothuis A; Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands., Drost J; Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.; Oncode Institute, Utrecht, The Netherlands., Perotti D; Predictive Medicine: Molecular Bases of Genetic Risk and Genetic Testing Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Koenig C; Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Brok J; Department of Pediatric Hematology and Oncology, Rigshospitalet, Copenhagen, Denmark.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Sep; Vol. 24 (9), pp. 837-843. Date of Electronic Publication: 2024 Jul 23.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/administration & dosage , Bevacizumab*/adverse effects , Bevacizumab*/pharmacology , Wilms Tumor*/drug therapy , Wilms Tumor*/pathology , Kidney Neoplasms*/drug therapy , Kidney Neoplasms*/pathology , Angiogenesis Inhibitors*/administration & dosage , Angiogenesis Inhibitors*/adverse effects , Angiogenesis Inhibitors*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Neoplasm Recurrence, Local*/drug therapy, Humans ; Child ; Prognosis ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/pathology

المؤلفون: Luo S; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China., Lai S; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China.; School of Pharmacy, Fujian Medical University, Fuzhou, China., Wu Y; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China.; School of Pharmacy, Fujian Medical University, Fuzhou, China., Hong J; Department of Radiotherapy, Cancer Center, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Radiotherapy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Fuzhou, China.; Key Laboratory of Radiation Biology of Fujian higher education institutions, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China., Lin D; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China., Lin S; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China., Huang X; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China., Xu X; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China., Weng X; Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, 350004, Fuzhou, China. wxh001@fjmu.edu.cn.; Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, 350212, Changle, Fujian Province, China. wxh001@fjmu.edu.cn.

المصدر: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2024 Sep; Vol. 200 (9), pp. 805-814. Date of Electronic Publication: 2024 Jun 03.

نوع المنشور: Journal Article; Comparative Study

بيانات الدورية: Publisher: Urban & Vogel Country of Publication: Germany NLM ID: 8603469 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1439-099X (Electronic) Linking ISSN: 01797158 NLM ISO Abbreviation: Strahlenther Onkol Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/therapeutic use , Bevacizumab*/economics , Cost-Benefit Analysis* , Radiation Injuries*/economics , Radiation Injuries*/etiology , Quality-Adjusted Life Years*, Humans ; China ; Decision Trees ; Nasopharyngeal Neoplasms/radiotherapy ; Nasopharyngeal Neoplasms/economics ; Nasopharyngeal Neoplasms/drug therapy ; Necrosis ; Adrenal Cortex Hormones/therapeutic use ; Adrenal Cortex Hormones/economics ; Angiogenesis Inhibitors/economics ; Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Agents, Immunological/economics ; Antineoplastic Agents, Immunological/therapeutic use ; Male ; Drug Costs ; Middle Aged ; Cost-Effectiveness Analysis